Old Web
English
Sign In
Acemap
>
authorDetail
>
Laura Dill-Morton
Laura Dill-Morton
Novartis
Biology
In vivo
Drug
Monoclonal antibody
Cancer
5
Papers
270
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
PEGylated Biopharmaceuticals Current Experience and Considerations for Nonclinical Development
2015
Toxicologic Pathology
Inge A. Ivens
William E. Achanzar
Andreas Baumann
Annamaria Brändli-Baiocco
Joy A. Cavagnaro
Maggie Dempster
B. Olympe Depelchin
Armando R. Irizarry Rovira
Laura Dill-Morton
Joan Lane
Birgit M. Reipert
Theodora W. Salcedo
Becky Schweighardt
Laurie Tsuruda
Peter Turecek
Jennifer Sims
Show All
Source
Cite
Save
Citations (99)
Anti-C5 mAb: In Vivo Effects Following Intravitreal Administration to Cynomolgus Monkeys
2014
Investigative Ophthalmology & Visual Science
Mark Milton
Laura Dill-Morton
Birgit Jaitner
David A Shaw
Timothy K. MacLachlan
Show All
Source
Cite
Save
Citations (1)
Chapter 27 – Carcinogenicity Assessment
2013
Daniel Morton
Carl L. Alden
Phillip M. Bartholomew
John M. Kreeger
Laura Dill-Morton
Show All
Source
Cite
Save
Citations (1)
Chapter 27 – Carcinogenicity Assessment
2013
Daniel Morton
Carl L. Alden
Phillip M. Bartholomew
John M. Kreeger
Laura Dill-Morton
Show All
Source
Cite
Save
Citations (1)
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
2010
mAbs
Frank R Brennan
Laura Dill-Morton
Sebastian Spindeldreher
Andrea Kiessling
Roy Allenspach
Adam Hey
Patrick Y. Muller
Werner Frings
Jennifer Sims
Show All
Source
Cite
Save
Citations (168)
1